Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss in adults over age 50 in developed countries, affecting approxim…
Medically reviewed by MedCentralHub Medical Review Board, Licensed Pharmacists & Physicians ·
Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss in adults over age 50 in developed countries, affecting approximately 11 million Americans and 170 million people worldwide. AMD causes progressive damage to the macula — the central region of the retina responsible for sharp, detailed vision. It exists in two forms: dry (non-neovascular) AMD, accounting for 85–90% of cases, and wet (neovascular) AMD, accounting for 10–15% but responsible for 90% of severe vision loss. AMD profoundly impacts quality of life, limiting reading, driving, facial recognition, and independent living.
This information is for educational purposes only. Always consult a qualified healthcare professional for diagnosis and personalized treatment.
Gradual, painless blurring of central vision (most common early symptom)
Distortion of straight lines (metamorphopsia) — hallmark of wet AMD
Central scotoma (blind spot) in central visual field
Difficulty reading, recognizing faces, or performing fine visual tasks
Colors appear less vivid or bright
Requiring brighter light for reading and near tasks
Drusen (yellow deposits under retina) — visible on dilated fundus exam; often asymptomatic in early stages
Sudden, dramatic central vision loss — suggests wet AMD or geographic atrophy progression
Dilated fundus examination — drusen, pigmentary changes, CNV, geographic atrophy
Optical coherence tomography (OCT) — gold standard for detecting subretinal fluid, CNV activity, retinal layer thickness
Fluorescein angiography (FA) — maps CNV pattern and leakage in wet AMD
OCT angiography (OCTA) — non-invasive CNV detection without dye injection
Amsler grid testing — patient self-monitoring for metamorphopsia or scotoma
Best corrected visual acuity (BCVA) assessment at each visit
Genetic testing — available but not routinely recommended for clinical management
Ranibizumab (Lucentis)
Anti-VEGF intravitreal injection. 0.5 mg monthly or treat-and-extend. Landmark ANCHOR and MARINA trials established efficacy. FDA-approved for neovascular AMD.
Aflibercept (Eylea)
VEGF-A, VEGF-B, and PlGF trap. 2 mg monthly x3, then every 2 months. VIEW trials showed non-inferiority to ranibizumab with less frequent dosing. High-dose Eylea HD (8 mg) approved for extended intervals.
Bevacizumab (Avastin)
Off-label anti-VEGF (full-length antibody). CATT trial showed comparable efficacy to ranibizumab. Widely used due to ~40-fold lower cost. Not FDA-approved for AMD but broadly accepted in clinical practice.
Faricimab (Vabysmo)
Dual VEGF-A and Ang-2 inhibitor. 6 mg q16w after loading doses in some patients. TENAYA and LUCERNE trials showed extended treatment intervals vs. aflibercept.
AREDS2 Supplements
For intermediate AMD or advanced AMD in one eye: Vitamin C 500 mg, Vitamin E 400 IU, Lutein 10 mg, Zeaxanthin 2 mg, Zinc 80 mg, Copper 2 mg daily. Reduces progression risk by ~25%.
Quit smoking immediately — single most impactful modifiable risk factor
Daily use of Amsler grid for home monitoring (report new distortion promptly)
AREDS2 vitamin supplementation for intermediate/advanced AMD
Eat Mediterranean-style diet rich in leafy green vegetables (kale, spinach — high lutein/zeaxanthin) and omega-3 fatty acids
Wear UV-blocking sunglasses outdoors
Control blood pressure, cholesterol, and blood sugar
Low vision rehabilitation if significant vision loss occurs (magnification aids, lighting optimization)
Regular dilated eye exams — annually for low risk, every 6 months for high risk or active disease
Prognosis
Dry AMD progresses slowly; advanced geographic atrophy causes significant central vision loss over years. Wet AMD can cause severe vision loss within weeks if untreated, but with timely anti-VEGF treatment, 90–95% of patients maintain vision, and 30–40% experience improvement. Long-term outcomes depend on treatment adherence, CNV pattern, and genetic factors. Bilateral advanced AMD occurs in 40–50% of patients with advanced disease in one eye. Vision loss is irreversible, but progression can be substantially slowed with consistent treatment and lifestyle modification.
Age-Related Macular Degeneration is a medical condition classified under Ophthalmology. Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss in adults over age 50 in developed countries, affecting approximately 11 million Americans and 170 million people worldwide. AMD causes progressive damage to the macula — the central region of the retina responsible for sharp, detailed vision. Understanding Age-Related Macular Degeneration is essential for patients, families, and healthcare providers to ensure timely diagnosis, appropriate treatment, and optimal outcomes.
Last reviewed by MedCentralHub Medical Review Board · MedCentralHub Editorial Policy
Medical Disclaimer
The information on this page is for educational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult your doctor or a qualified healthcare provider with any questions about a medical condition.